Stocks · News reference

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

Aug 21, 2026, 3:44 PMBenzinga Newsdesk

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 21, 2026, 3:44 PM
Checked: Aug 21, 2026, 3:44 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 11, 2026, 2:48 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
Read original at benzinga
SNDX
BenzingaAug 5, 2026, 1:00 PMBenzinga Newsdesk
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.
Read original at benzinga
SNDX
BenzingaAug 5, 2026, 11:10 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
Read original at benzinga
SNDX